Core Viewpoint - The Gross Law Firm is notifying shareholders of Replimune Group, Inc. about a class action lawsuit due to alleged misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 22, 2024, to July 21, 2025 [3]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, leading to misleading statements about Replimune's business and operations [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiff [4]. - Registration allows shareholders to receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had re ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Replimune Group, Inc. regarding a class action lawsuit related to misleading statements made by the company during the class period from November 22, 2024, to July 21, 2025 [1] - Allegations include that Replimune Group overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate and not well-controlled, leading to materially false and misleading statements about the company's business and operations [1] - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiffs and to receive updates on the case [2] Company Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3]

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/ ...

Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. for allegedly making materially false and misleading statements regarding its business and product prospects during the class period from November 22, 2024, to July 21, 2025 [1][2]. Group 1: Allegations Against Replimune - The complaint claims that Replimune overstated the trial prospects for its lead product candidate, leading to materially false and misleading statements about the company's business and operations [2]. - Defendants are accused of failing to disclose material facts about the company's business, operations, and prospects throughout the class period [2]. Group 2: Lead Plaintiff Process - Investors in Replimune have until September 22, 2025, to seek appointment as a lead plaintiff representative of the class, or they may choose to remain absent class members [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and has a reputation for prosecuting class actions and recovering billions for victims of corporate misconduct [4]. - The firm encourages Replimune investors who have suffered significant losses to contact them for more information [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Replimune Group, Inc. about a class action lawsuit due to alleged misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 22, 2024, to July 21, 2025 [3]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, leading to misleading statements about Replimune's business and operations [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock [5].

Group 1 - A class action has been filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024, and July 21, 2025 [1] - Robbins LLP is investigating allegations that Replimune Group, Inc. misled investors regarding the viability of its IGNYTE trial, claiming that the company overstated the trial's prospects and failed to disclose material issues [2] - On July 22, 2025, Replimune announced it received a complete response letter (CRL) from the FDA, indicating that the IGNYTE trial was not considered adequate and well-controlled, leading to a significant stock price drop of $9.52 per share, or 77.24%, closing at $2.80 per share [3] Group 2 - Shareholders interested in serving as lead plaintiff must file their papers with the court by September 22, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives made false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [6][7]. - Following the FDA's Complete Response Letter on July 22, 2025, Replimune's stock fell over 73% during intraday trading, indicating significant investor losses [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial, overstating its prospects despite known material issues, leading to the FDA deeming the trial inadequate [2] - Defendants' statements about Replimune's business and operations were claimed to be materially false and misleading, lacking a reasonable basis at all relevant times [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. for alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be inadequate by the defendants, leading to misleading statements about Replimune's business and operations [2] - The lawsuit seeks to recover losses for investors adversely affected by these alleged misrepresentations [1] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]